Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.54 |
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | JAK2 | O60674 | 4/20 | 0.54 |
| ▸ | ITK | Q08881 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | STK16 | O75716 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | MST1R | Q04912 | 2/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.54 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.54 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190333 | 0.95 | SYK (0.49) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL190375 | 0.83 | SYK (0.70) | SYKEGFRJAK2AURKAMAPK8 | |
| SCHEMBL190515 | 0.82 | SYK (0.61) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL13007744 | 0.81 | SYK (0.60) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL14837327 | 0.81 | SYK (0.74) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL189926 | 0.80 | SYK (0.46) | SYKEGFRJAK2ITKLCK | |
| SCHEMBL2101181 | 0.79 | SYK (0.47) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL2100867 | 0.79 | SYK (0.47) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL19297727 | 0.79 | SYK (0.54) | SYKEGFRJAK2ITKJAK1 | |
| SCHEMBL2101544 | 0.78 | SYK (0.61) | SYKEGFRJAK2ITKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814878-B1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1814878-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2006068770-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | SSB, SPHK2, PKD2 | SYK 1386/4885EGFR 4674/4885JAK2 2709/4885 |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | SYK 1168/4885EGFR 4643/4885JAK2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.